The Next Step In A Cure for Stage IV Triple-Negative Breast Cancer is Pam50 And Archetypes

Robert Graham Ph.D. Reporting From New York City US Tennis Open 2012

---

The Next Step In A Cure for Stage IV Triple-Negative Breast Cancer is Pam50 And Archetypes

---

The next step in a cure for Stage IV Triple-Negative Breast Cancer starts with

Gennxeix Pam50 and Archetypes. Yes Archetypal images represent as-yet-unconscious

potentials for a breast cancer patient. Therapy helps patients to relate to archetypal images consciously, thereby releasing their energy for growth.

Brought To You By gloStream How PAM50 Breast Cancer Intrinsic Classifier works. Selene Flores CEO of Gennxeix Biotech says using the PAM50 Breast Cancer Intrinsic Classifier,to show how to characterize error within an MVA, and how these errors may affect results reported

to clinicians. First we estimated the error distribution for measured factors within the PAM50 assay by performing repeated measures on four archetypal samples representative of the major breast cancer tumor subtypes. Then, using the error distributions and the original archetypal sample data, we used Monte Carlo simulations to generate a sufficient number of simulated samples. The effect of these errors on the PAM50 tumor subtype classification was estimated by measuring subtype reproducibility after classifying all simulated samples. Subtype reproducibility was measured as the percentage of simulated samples classified identically to the parent sample. The simulation was thereafter repeated on a large, independent data set of samples from the GEICAM 9906 clinical trial. Simulated samples from the GEICAM sample set were used to explore a more realistic scenario where, unlike archetypal samples, many samples are not easily classified Purpose Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy. Patients and Methods In this randomized phase II trial, patients with metastatic TNBC received anti-EGFR antibody cetuximab (400 mg/m2 load then 250 mg/m2 per week intravenously [IV]) alone, with carboplatin (area under the curve of 2, once per week IV) added after progression or as concomitant therapy from the beginning. Response rate (RR) was the primary end point; others included time to progression (TTP), overall survival (OS), and toxicity. Embedded correlative studies included molecular subtyping on archival tissue. Fresh tumor tissue before and after 7 to 14 days of therapy was used for microarray analyses exploring EGFR pathway activity and inhibition. Gennxeix uses Genomics modeling for drivers and passenger math models to locate genes associated with Stage IV Triple-Negative Breast Cancer. The Genes are Luminal B. ✍ BCL2*. ✍ CXXC5. ✍ EGFR*. ✍ KIF2C*. ✍ MDM2*. ✍ MKI67*. ✍ ORC6L*. ✍ PGR*. ✍ PHGDH To take advantage of the full array of options physicians now have with genomics it important that your breast cancer doctors have EMR Electronic Health Records to capture a patients Carl Jung Myers-Briggs Type Indicator (MBTI) scores and provide the breast cancer patient with the best possible care. Gennxeix Similarly, the development of systematic approaches to identify somatic mutations has prompted exhaustive analyses of changes in cancer genomes, including copy-number changes (deletions and amplifications of DNA), rearrangements, small insertions and deletions, and point mutations